Biotechnology and Bioengineering · 2018 · 47 citations · 31 references
Life SciencesBiochemistryMolecular BiologyEnzymologyProtein BiochemistryProteomicsEnzyme InhibitionEnzyme StabilityProtein DegradationProtein TurnoverProteolytic EnzymesProteolytic ProcessingNucleasesProtease InhibitionProtease InhibitorsProtease-mediated Protein DegradationProteolysis ReductionProteolytic ActivityTherapeutic ProteinsTranscription Activator-like Effector Nuclease Knockout
An increasing number of nonantibody format proteins are entering clinical development. However, one of the major hurdles for the production of nonantibody glycoproteins is host cell-related proteolytic degradation, which can drastically impact developability and timelines of pipeline projects. Chinese hamster ovary (CHO) cells are the preferred production host for recombinant therapeutic proteins. Using protease inhibitors, transcriptomics, and genetic knockdowns, we have identified, out of the >700 known proteases in rodents, matriptase-1 as the major protease involved in the degradation of recombinant proteins expressed in CHO-K1 cells. Subsequently, matriptase-1 was deleted in CHO-K1 cells using "transcription activator-like effector nucleases" (TALENs) as well as zinc-finger nucleases (ZFNs). This resulted in a superior CHO-K1 matriptase (KO) cell line with strongly reduced or no proteolytic degradation activity toward a panel of recombinantly expressed proteins. The matriptase KO cell line was evaluated in spike-in experiments and showed little or no degradation of proteins incubated in culture supernatant derived from the KO cells. This effect was confirmed when the same proteins were recombinantly expressed in the KO cell line. In summary, the combination of novel cell line engineering tools, next-generation sequencing screening methods, and the recently published Chinese hamster genome has enabled the development of this novel matriptase KO CHO cell line capable of improving expression yields of intact therapeutic proteins.
31
A Programmable Dual-RNA–Guided DNA Endonuclease in Adaptive Bacterial Immunity
Martin Jínek, Krzysztof Chylinski, Ines Fonfara et al. · Science · 2012 · 17.3K citations · Full text
Multiplex Genome Engineering Using CRISPR/Cas Systems
Le Cong, F. Ann Ran, David Cox et al. · Science · 2013 · 15.7K citations
Genetic engineering of human pluripotent cells using TALE nucleases
Dirk Hockemeyer, Haoyi Wang, Samira Kiani et al. · Nature Biotechnology · 2011 · 1.1K citations
Biopharmaceutical benchmarks 2014
Gary Walsh · Nature Biotechnology · 2014 · 1K citations
The genomic sequence of the Chinese hamster ovary (CHO)-K1 cell line
Xun Xu, Harish Nagarajan, Nathan E. Lewis et al. · Nature Biotechnology · 2011 · 793 citations · Full text